Read about the new Rx products featured in May.
MARKETED BY: Lexicon Pharmaceuticals
INDICATION: The FDA has approved Xermelo (telotristat ethyl) 250 mg as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
DOSAGE FORM: Tablets: 250 mg
FOR MORE INFORMATION: xermelo.com
MARKETED BY: AstraZeneca
INDICATION: AstraZeneca has announced the FDA approval of once-daily Qtern (10 mg dapagliflozin and 5 mg saxagliptin) for the treatment of type 2 diabetes. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who have inadequate control with dapagliflozin or who are already being treated with dapagliflozin and saxagliptin.
DOSAGE FORM: Tablet: 10 mg dapagliflozin/5 mg saxagliptin
FOR MORE INFORMATION: astrazeneca.com
MARKETED BY: Novartis
INDICATION: The FDA has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
DOSAGE FORM: TABLETS: 200 mg
FOR MORE INFORMATION: Novartis.com
MARKETED BY: Merck
INDICATION: The FDA has approved Keytruda’s indication for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapy.
DOSAGE FORM: Injection: 200 mg for adults; up to 200 mg for pediatrics
FOR MORE INFORMATION: Keytruda.com